External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

BACKGROUND Vancomycin is one of the most evaluated antibiotics in neonates using modeling and simulation approaches. However no clear consensus on optimal dosing has been achieved. The objective of the present study was to perform an external evaluation of published models, in order to test their predictive performances in an independent dataset and to identify the possible study-related factors influencing the transferability of pharmacokinetic models to different clinical settings. METHOD Published neonatal vancomycin pharmacokinetic models were screened from the literature. The predictive performance of 6 models was evaluated using an independent dataset (112 concentrations from 78 neonates). The evaluation procedures used simulation-based diagnostics (visual predictive check [VPC] and normalized prediction distribution errors [NPDE]). RESULTS Differences in predictive performances of models for vancomycin pharmacokinetics in neonates were found. The mean of NPDE for 6 evaluated models were 1.35, -0.22, -0.36, 0.24, 0.66, 0.48, respectively. These differences were explained, at least partly, by taking into account the method used to measure serum creatinine concentrations. The adult conversion factor of 1.3 (enzymatic to Jaffé) was tested with an improvement in the VPC and NPDE, but it still need to be evaluated and validated in neonates. Differences were also identified between analytical methods for vancomycin. CONCLUSION The importance of analytical techniques for serum creatinine concentrations and vancomycin as a predictor of vancomycin concentrations in neonates has been confirmed. Dosage individualisation of vancomycin in neonates should consider not only patients' characteristics and clinical conditions, but also the methods used to measure serum creatinine and vancomycin.

[1]  L. Lewi,et al.  Creatinaemia at birth is equal to maternal creatinaemia at delivery: does this paradigm still hold? , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  Lisa Tang,et al.  Evaluation of Vancomycin Dosing Regimens in Preterm and Term Neonates Using Monte Carlo Simulations , 2012, Pharmacotherapy.

[3]  D. Mekahli,et al.  Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[4]  V. Jn.  Getting the dose of vancomycin right in the neonate. , 2011, CP 2011.

[5]  C. Oudin,et al.  Vancomycin prescription in neonates and young infants: toward a simplified dosage , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[6]  F. Bellanti,et al.  Modelling and simulation as research tools in paediatric drug development , 2011, European Journal of Clinical Pharmacology.

[7]  J. Peris,et al.  Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. , 2010, British journal of clinical pharmacology.

[8]  B. Charles,et al.  Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination , 2010, Antimicrobial Agents and Chemotherapy.

[9]  M. Danhof,et al.  The role of population PK–PD modelling in paediatric clinical research , 2010, European Journal of Clinical Pharmacology.

[10]  Michael Barras,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. , 2010, The Clinical biochemist. Reviews.

[11]  Mats O. Karlsson,et al.  Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.

[12]  Meindert Danhof,et al.  Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. , 2009, Drug discovery today.

[13]  France Mentré,et al.  Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R , 2008, Comput. Methods Programs Biomed..

[14]  F. de Zegher,et al.  Renal Drug Clearance in Preterm Neonates: Relation to Prenatal Growth , 2007, Therapeutic drug monitoring.

[15]  M. Peake,et al.  Measurement of serum creatinine--current status and future goals. , 2006, The Clinical biochemist. Reviews.

[16]  France Mentré,et al.  Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.

[17]  H. Mulla,et al.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. , 2005, British journal of clinical pharmacology.

[18]  Y. Kagawa,et al.  Factors Influencing the Overestimation of Plasma Vancomycin Concentrations Measured by the Abbott TDx Technique , 2005, Therapeutic drug monitoring.

[19]  J. Sobel,et al.  Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. , 2004, Infectious disease clinics of North America.

[20]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[21]  N. Matsuura,et al.  Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates , 2004, Antimicrobial Agents and Chemotherapy.

[22]  J. Connor,et al.  The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants , 2001, Journal of clinical pharmacology.

[23]  R. Schoemaker,et al.  Vancomycin population pharmacokinetics in neonates , 2000, Clinical pharmacology and therapeutics.

[24]  D. Lebel,et al.  A Population Pharmacokinetic Model for Vancomycin in Pediatric Patients and Its Predictive Value in a Naive Population , 2000, Antimicrobial Agents and Chemotherapy.

[25]  Patrick F. Smith,et al.  Accuracy of Measured Vancomycin Serum Concentrations in Patients with End-Stage Renal Disease , 1999, The Annals of pharmacotherapy.

[26]  A. Thomson,et al.  Pharmacokinetics and dose requirements of vancomycin in neonates , 1999, Archives of disease in childhood. Fetal and neonatal edition.

[27]  A. Falcão,et al.  Pharmacokinetics:The Kinetic Profile of Vancomycin in Neonates , 1998, The Journal of pharmacy and pharmacology.

[28]  R. Schoemaker,et al.  Tobramycin population pharmacokinetics in neonates * , 1997 .

[29]  R. Behrens,et al.  Eosinophilic colitis: a differential diagnosis of allergic colitis. , 1997, European journal of pediatrics.

[30]  M. Levine,et al.  Vancomycin Pharmacokinetics and Dosing in Premature Neonates , 1995, Therapeutic drug monitoring.

[31]  R. Brundage,et al.  Population pharmacokinetics of vancomycin in neonates , 1994, Clinical pharmacology and therapeutics.

[32]  E. Maderazo,et al.  Serum protein-binding characteristics of vancomycin , 1993, Antimicrobial Agents and Chemotherapy.

[33]  N. Madias,et al.  Serum creatinine as an index of renal function: new insights into old concepts. , 1992, Clinical chemistry.

[34]  K. Chan,et al.  Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. , 1989, Therapeutic drug monitoring.

[35]  W. Bennett,et al.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects , 1988, Clinical pharmacology and therapeutics.

[36]  B. Bruguerolle,et al.  Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.

[37]  J. N. van den Anker.  Getting the dose of vancomycin right in the neonate. , 2011, International journal of clinical pharmacology and therapeutics.

[38]  Imti Choonara,et al.  Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. , 2011, Clinical pharmacokinetics.

[39]  P. Tulkens,et al.  International Journal of Antimicrobial Agents Correlation between Free and Total Vancomycin Serum Concentrations in Patients Treated for Gram-positive Infections , 2022 .

[40]  A. Prigent,et al.  Monitoring renal function and limitations of renal function tests. , 2008, Seminars in nuclear medicine.

[41]  Michel Tod,et al.  Facilitation of Drug Evaluation in Children by Population Methods and Modelling , 2008, Clinical pharmacokinetics.

[42]  N. Holford,et al.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. , 2007, British journal of clinical pharmacology.

[43]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[44]  M. Mongelli,et al.  A fetal growth standard derived from multiple modalities. , 2001, Early human development.

[45]  J. N. van den Anker.  Renal function in preterm infants. , 1997, European journal of pediatrics.